Absence of systemic hormonal effects in an oestradiol diether topically active on the vaginal mucosa

Wolff, J. P.; Cachelou, R.; Gueritee, N

doi:10.1016/0378-5122(82)90054-8

Cited by 25 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first reassuring and most reliable data on promestriene low absorption emerged from a randomized, double-blind controlled trial on patients with cancer [15].…”

Section: Promestriene Use In Patients With Cancermentioning

confidence: 99%

See 1 more Smart Citation

Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment

Pup¹,

Francia²,

Cavaliere³

et al. 2013

Anti-Cancer Drugs

View full text Add to dashboard Cite

Urogenital symptoms resulting from estrogen deficiency are common problems that impair quality of life and sexuality. Potentially, one out of three postmenopausal women could benefit from a vaginal estrogen therapy, but the fear of systemic absorption limits its use. Promestriene used vaginally to relieve vaginal atrophy is a locally effective estrogen that has not shown systemic estrogenic effects. Thus, it could be a first-line option for those who necessitate a minimal or ideally no vaginal absorption, particularly in symptomatic cancer patients. There are little data available in the literature, mostly consisting of small, open-label, short duration studies, and few randomized-controlled studies. After a long-term market experience (almost 40 years), in 34 countries, and millions of pieces prescribed, the side effects were very rarely reported in pharmacovigilance data, whereas the effectiveness to relieve atrophy was good. To further improve promestriene safety, especially in estrogen-sensitive cancer patients, a very low dose is used from the beginning, starting from half or less of the usual dose, and then gradually increased till the minimum effective dose, which could further reduce its already minimal vaginal absorption.

show abstract

“…The first reassuring and most reliable data on promestriene low absorption emerged from a randomized, double-blind controlled trial on patients with cancer [15].…”

Section: Promestriene Use In Patients With Cancermentioning

confidence: 99%

“…In two randomized, double-blind trials, promestriene was compared with placebo and no differences in systemic activity were documented [10,15].…”

Section: Evidence and Reasons Of The Low Vaginal Absorption Of Promesmentioning

confidence: 99%

Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment

Pup¹,

Francia²,

Cavaliere³

et al. 2013

Anti-Cancer Drugs

View full text Add to dashboard Cite

show abstract

“…Cependant, plusieurs études, sur des petits effectifs dont une seule étude en double insu, celle de Wolff, semblent montrer que le promestriène (Colpotrophine ® ) n'a aucun effet systémique, agissant directement sur la muqueuse vaginale en étant incapable, sous sa forme de dié-theroxyde, de traverser l'épithélium malpighien pour rejoindre la circulation générale [45]. Pour pouvoir recommander l'utilisation de la Colpotrophine ® dans ce contexte, il serait nécessaire d'avoir des études sur des effectifs beaucoup plus importants.…”

Section: Sécheresse Vaginaleunclassified

Interférence du cancer du sein sur la sexualité

Mimoun¹,

Veluire²,

Zarca³

et al. 2011

Oncologie

View full text Add to dashboard Cite

“…However, no clinical study has so far been carried out to examine the effect of topical oestrogen on the nasal mucosa of the patients with HHT. Topical oestrogen was shown to give no systemic hormonal effects 74 avoiding the potential side‐effects of systemic therapy 64,65 . Further studies on the effect of topical oestrogen on the nasal mucosa of HHT patients seem appropriate and necessary.…”

Section: Treatmentmentioning

confidence: 99%

Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): otorhinolaryngological manifestations

2001

View full text Add to dashboard Cite

Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant disorder affecting blood vessels of the skin, mucous membrane and viscera. The otorhinolaryngologist is the commonest clinician involved in management as epistaxis occurs in 93% of the patients. As marked advances have recently been made regarding the pathogenesis and management of the condition, the otorhinolaryngological perspective is reviewed.

show abstract

Absence of systemic hormonal effects in an oestradiol diether topically active on the vaginal mucosa

Cited by 25 publications

References 13 publications

Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment

Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment

Interférence du cancer du sein sur la sexualité

Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): otorhinolaryngological manifestations

Contact Info

Product

Resources

About